The role of entecavir in the treatment of chronic hepatitis B

Figures & data

Figure 1 Comparison of responses to treatment (HBeAg seroconversion and log reduction of serum HBV DNA) of HBeAg positive chronic hepatitis B. Lau et al. 2005. N Engl J Med, 352:2682–95. Dienstag et al. 1999. N Engl J Med, 341:1256–63. Marcellin et al. 2005. EASL, Abstract 73. Lai et al. 2005. AASLD, Abstract 72404.(LB1) Chang et al. 2004 AASLD, Abstract 70. Telbivudine package insert. Marcellin et al. 2003. N Engl J Med. 348:808–16. Chang et al. 2006. N Engl J Med. 354:1001–10.

Figure 2 The chemical structure of entecavir.

Table 1 Comparison of entecavir vs lamivudine in HBeAg positive and HBeAg-negative treatment-naïve patients with chronic hepatitis B (CHB)

	HBeAg (+) CHB				HBeAg (−) CHB
	LAM		ETV		LAM		ETV
	Year 1	Year 2	Year 1	Year 2	Year 1	Year 2	Year 1	Year 2
Undetectable	36%	39%	67%	80%	72%	77%	90%	94%
HBV DNA
ALT normal	60%	77%	68%	84%	71%	84%	78%	89%
HBeAg loss	20%	28%	22%	32%	NA	NA	NA	NA
HBeAg seroconversion	18%	25%	21%	31%	NA	NA	NA	NA
Histologic improvement	62%	NA	72%	NA	61%	NA	70%	NA
HBV resistance	13%	NA	0%	0%	6%	NA	0%	0%

Abbreviations: CHB, chronic hepatitis B; ETV, entecavir; LAM, lamivudine; ALT, alanine aminotransferase; HBV, hepatitis B virus; NA, non applicable; vs, versus. (Gish et al 2005; Chang et al 2006a; Lai et al 2006b; Shouval et al 2006).

Table 2 Comparison of entecavir vs lamivudine in HbeAg positive lamivudine-resistance patients with chronic hepatitis B (CHB)

	Week 48		Week 96
	ETV	LAM	ETV	LAM
Undetectable	19%	1%	30%	1%
HBV DNA
ALT	61%	15%	85%	29%
Normal
HBeAg	8%	3%	16%	4%
seroconversion
Histologic	55%	28%	NA	NA
improvement
ETV	6%	NA	9%	NA
resistance

Abbreviations: ETV, entecavir; LAM, lamivudine; ALT, alanine aminotransferase; NA, non applicable; vs, versus.

(Sherman et al 2006; Yurdaydin et al 2006)

Figure 3 The rate of Entecavir resistance in Naïve and Lamivudine-resistance chronic hepatitis B patients during 3 years of treatment. Colonno RJ. AASLD 2006. Abstract 110.

LauGKKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis BN Engl J Med200535226829515987917

 PubMed Web of Science ®Google Scholar

MarcellinPChangTTLimSGIncreasing serologic, virologic and biochemical response over time to Adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patientsJ Hepatol2005422S312

 Google Scholar

MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitisBN Engl J Med20033488081612606735

 PubMed Web of Science ®Google Scholar

GishRGChangTTDe ManREntecavir results in substantial virologic and biochemical improvement and HBeAg seroconvertion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022)Hepatology200542267A268A

 Web of Science ®Google Scholar

ChangTTGishRGDe ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006a35410011016525137

 PubMed Web of Science ®Google Scholar

LaiCLShouvalDLokASEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med2006b35410112016525138

 PubMed Web of Science ®Google Scholar

ShouvalDHatzisGKitisGContinued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) hepatitis B patients (Study ETV-027)J Hepatol200644S182

 Web of Science ®Google Scholar

ShermanMYurdaydinCSollanoJEntecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis BGastroenterology200613020394916762627

 PubMed Web of Science ®Google Scholar

YurdaydinCSollanoJHadziyannisSJEntecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory HBeAg (+) chronic hepatitis B patients (ETV-026)J Hepatol200644S36

 Web of Science ®Google Scholar